Option Care Health Valuation
Is OPCH * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of OPCH * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: OPCH * (MX$628.01) is trading below our estimate of fair value (MX$1116.18)
Significantly Below Fair Value: OPCH * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OPCH *?
Other financial metrics that can be useful for relative valuation.
What is OPCH *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$5.37b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.4x |
Enterprise Value/EBITDA | 16.5x |
PEG Ratio | 2.3x |
Price to Earnings Ratio vs Peers
How does OPCH *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 74.6x | ||
CRVL CorVel | 70.3x | n/a | US$5.5b |
LALPATHLAB Dr. Lal PathLabs | 71.4x | 15.8% | ₹272.6b |
MCOV B Medicover | 109.5x | 38.6% | SEK 28.5b |
600763 Topchoice Medical | 47.1x | 15.7% | CN¥23.8b |
OPCH * Option Care Health | 25.4x | 10.9% | Mex$5.4b |
Price-To-Earnings vs Peers: OPCH * is good value based on its Price-To-Earnings Ratio (25.4x) compared to the peer average (74.6x).
Price to Earnings Ratio vs Industry
How does OPCH *'s PE Ratio compare vs other companies in the Global Healthcare Industry?
Price-To-Earnings vs Industry: OPCH * is expensive based on its Price-To-Earnings Ratio (25.4x) compared to the Global Healthcare industry average (23.2x).
Price to Earnings Ratio vs Fair Ratio
What is OPCH *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 25.4x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate OPCH *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.